Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Public Storage (PSA) vs Summit Therapeutics Inc (SMMT) Price & Performance

Public StorageTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Public Storage vs Summit Therapeutics Inc — how do they compare? Public Storage trades at $311.4 (market cap $54.39B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: Public Storage is far larger — about 4.8× Summit Therapeutics Inc's market cap, and Public Storage pays a 3.87% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

PSASMMT
Market Cap
$54.39B$11.34B
Sector
Real EstateHealth
52-Week High
$329.64$29.32
52-Week Low
$258.44$13.05
Enterprise Value
$68.63B$10.76B
Dividend Yield
3.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Public Storage

Public Storage (PSA) trades at $309.75, down 2.61% on the day, with a bearish technical signal but strong fundamentals including a 39.16% net income margin and consistent earnings beats. Recent developments include the pending acquisition of National Storage Affiliates and a $3.00 dividend payment scheduled for June 30, 2026. The stock is near its 52-week high of $331.00, reflecting investor confidence in its growth trajectory and sector leadership.

The outlook remains positive due to robust profitability, strategic expansions into Canada, and analyst consensus pointing to a $332.25 price target. Key risks include integration challenges from acquisitions and interest rate sensitivity. With 65.72% of analysts rating it Hold, the stock offers steady income potential but requires monitoring of execution risks and market volatility.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Public Storage

Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.

Read more on PSA

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT